RHJA
OSIR

Rice Hall James & Associates’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Rice Hall James & Associates’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-62,240
Closed -$1.15M – 338
2015
Q3 		$1.15M Buy
+62,240
New +$1.2M 0.07% 227

Other funds holding OSIR

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

Rice Hall James & Associates's OSIR Position: Q4 2015 in Review

Rice Hall James & Associates sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q4 2015, closing a stake of 62,240 shares — an estimated $1.15M sold.

Rice Hall James & Associates first reported a position in OSIR in Q3 2015 and held it in 1 quarter. The position peaked at $1.15M in Q3 2015. 81 funds tracked by Wall St. Rank hold OSIR as of Q4 2015.

  • Rice Hall James & Associates reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Rice Hall James & Associates sold 62,240 Osiris Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $1.15M.
  • Rice Hall James & Associates first reported a position in Osiris Therapeutics, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • Rice Hall James & Associates's Osiris Therapeutics, Inc. Common Stock position peaked at $1.15M in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Rice Hall James & Associates's 13F filing for Q4 2015, filed 28 Jan 2016.